Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

4/9/2025

Janusmed kön och genus

Janusmed kön och genus – Lamotrigin Orifarm

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Lamotrigin Testmiljö

Lamotrigin

Klass : C

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Crisomet, Labileno, Lamictal, Lamictal 25 mg disperguojamosios, Lamoca......

Crisomet, Labileno, Lamictal, Lamictal 25 mg disperguojamosios, Lamocare, Lamotrigin 1A Farma, Lamotrigin 2care4, Lamotrigin Abacus Medicine, Lamotrigin Actavis, Lamotrigin Aristo, Lamotrigin Arrow, Lamotrigin Aurobindo, Lamotrigin BMM Pharma, Lamotrigin Bluefish, Lamotrigin EQL, Lamotrigin Ebb, Lamotrigin Hexal, Lamotrigin Medochemie, Lamotrigin Mylan, Lamotrigin Orifarm, Lamotrigin Orion, Lamotrigin Teva, Lamotrigin ratiopharm
ATC-koder

N03AX09

N03AX09
Substanser

lamotrigin

lamotrigin
Sammanfattning

Det saknas studier som jämför den krampförebyggande effekten mellan män och kvinnor. En studie har visat att män svarar bättre än kvinnor på behandling med lamotrigin vid svårbehandlad bipolär affektiv sjukdom. Den övergripande biverkningsprofilen för lamotrigin är likartad för män och kvinnor. Yrsel har i en studie rapporterats vara vanligare hos kvinnor. Under graviditet sjunker vanligen koncentrationen av lamotrigin, tät monitorering av detta och korrigering av dos krävs för att upprätthålla krampförebyggande effekt. Post-partum måste dosen normaliseras för att undvika överdosering.

Det saknas studier som jämför den krampförebyggande effekten mellan män och kvinnor. En studie har visat att män svarar bättre än kvinnor på behandling med lamotrigin vid svårbehandlad bipolär affektiv sjukdom. Den övergripande biverkningsprofilen för lamotrigin är likartad för män och kvinnor. Yrsel har i en studie rapporterats vara vanligare hos kvinnor. Under graviditet sjunker vanligen koncentrationen av lamotrigin, tät monitorering av detta och korrigering av dos krävs för att upprätthålla krampförebyggande effekt. Post-partum måste dosen normaliseras för att undvika överdosering.
Background

Pharmacokinetics and dosing
Population analysis shows that pharmacokinetics of lamotrigine is similar in men and women [1-3]. However, a meta-analysis found that the volume of distribution was 27% lower in women than men. This difference persisted even when the effect of weight was taken into account. In all, 22/289 women were receiving concomitant therapy with various oral contraceptives. But in this study, oral contraceptives exhibited little effect on the pharmacokinetics of lamotrigine [3]. Dose adjustment based on patient’s sex appear to be unnecessary [2, 3]. During pregnancy, elimination of lamotrigine is increased necessitating therapeutic drug monitoring and dose adjustment, se below.

Effects
A small U.S. randomized clinical trial (18 men, 27 women, aged 20-67 years) has analysed possible clinical predictors of positive response to lamotrigine monotherapy in adults with refractory affective bipolar disorder. Male sex was associated with good response to lamotrigine [4].

Adverse effects
In a randomized parallel study conducted by the pharmaceutical company comparing pl......

Visa hela bakgrundstexten

# Pharmacokinetics and dosing Population analysis shows that pharmacokinetics of lamotrigine is similar in men and women [1-3]. However, a meta-analysis found that the volume of distribution was 27% lower in women than men. This difference persisted even when the effect of weight was taken into account. In all, 22/289 women were receiving concomitant therapy with various oral contraceptives. But in this study, oral contraceptives exhibited little effect on the pharmacokinetics of lamotrigine [3]. Dose adjustment based on patient’s sex appear to be unnecessary [2, 3]. During pregnancy, elimination of lamotrigine is increased necessitating therapeutic drug monitoring and dose adjustment, se below. # Effects A small U.S. randomized clinical trial (18 men, 27 women, aged 20-67 years) has analysed possible clinical predictors of positive response to lamotrigine monotherapy in adults with refractory affective bipolar disorder. Male sex was associated with good response to lamotrigine [4]. # Adverse effects In a randomized parallel study conducted by the pharmaceutical company comparing placebo and 300 and 500 mg/day of lamotrigine, the overall adverse reaction profile for lamotrigine was similar between women and men. The only adverse reaction for which the reports were greater than 10% more frequent in women than men was dizziness (difference = 16.5%) [1]. A retrospective analysis of patients on antiepileptic drug treatment showed fertile women to have a higher risk for skin reactions than men when treated with lamotrigine [5]. # Reproductive health issues Semen quality, sexual function and sex hormones in men with epilepsy are not affected by treatment with lamotrigine, levetiracetam, or oxcarbazepine, according to a randomized controlled trial including 38 adult men with newly diagnosed epilepsy [6]. Reports of sexual dysfunction caused by levetiracetam or oxcarbazepine are limited to case reports. Larger studies suggest that lamotrigine, levetiracetam and oxcarbazepine can improve sexual function [6, 7].  During pregnancy, clearance of lamotrigine increases progressively until the 32nd gestational week when it may be 2-3 times higher than pre-pregnancy levels. This is caused by induction of glucuronidation. After delivery the lamotrigine elimination rate drops rapidly and reach the pre-pregnant levels within the first 2-3 weeks postpartum [3, 8]. During mid and late pregnancy, serum concentrations of lamotrigine may decline to 30-50% of pre-pregnancy levels, with an increased frequency of seizures [8, 9]. Therefore, close monitoring of lamotrigine concentrations throughout the entire pregnancy and postpartum is recommended [10]. Lamotrigine has little effect on mixed-function oxygenase enzymes, it would not be expected that estrogen and progestin clearance would be altered. Previous investigation suggests that lamotrigine has no effect on the clearance of ethinyl estradiol and levonorgestrel (30/150 µg) and no alternations in menstrual pattern were noted [9].  Regarding drug-drug interactions aspects, please consult Janusmed Interactions (in Swedish, Janusmed interaktioner). Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler kvinnor än män hämtade ut tabletter innehållande lamotrigin (ATC-kod N03AX09) på recept i Sverige år 2019, totalt 37 215 kvinnor och 22 114 män. Det motsvarar 7,3 respektive 4,3 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 25-34 år hos båda könen. I genomsnitt var tabletter innehållande lamotrigin 1,7 gånger vanligare hos kvinnor [11].
Referenser

Visa referenser

  1. Lamictal (lamotrigine). DailyMed [www]. U.S. National Library of Medicine. [updated 2019-08-27, cited 2019-09-20].

  2. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol. 1997;43:457-65.

  3. Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol. 1999;39:373-84.

  4. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002;51:253-60.

  5. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007;48:1360-5.

  6. Wu D, Chen L, Ji F, Si Y, Sun H. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Epilepsia. 2018;59(7):1344-1350.

  7. Yogarajah M, Mula M. Sexual Dysfunction in Epilepsy and the Role of Anti-Epileptic Drugs. Curr Pharm Des. 2017;23(37):5649-5661.

  8. Sabers A, Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol. 2009;22:157-61.

  9. Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS, editor. Handbook of Clinical Gender Medicine. 1st ed. Karger; 2012.

  10. Pennell PB. 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia. 2006;47 Suppl 1:46-53.

  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Lamictal (lamotrigine). DailyMed [www]. U.S. National Library of Medicine. [updated 2019-08-27, cited 2019-09-20].
  2. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol. 1997;43:457-65.
  3. Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol. 1999;39:373-84.
  4. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002;51:253-60.
  5. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007;48:1360-5.
  6. Wu D, Chen L, Ji F, Si Y, Sun H. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Epilepsia. 2018;59(7):1344-1350.
  7. Yogarajah M, Mula M. Sexual Dysfunction in Epilepsy and the Role of Anti-Epileptic Drugs. Curr Pharm Des. 2017;23(37):5649-5661.
  8. Sabers A, Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol. 2009;22:157-61.
  9. Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS, editor. Handbook of Clinical Gender Medicine. 1st ed. Karger; 2012.
  10. Pennell PB. 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia. 2006;47 Suppl 1:46-53.
  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]
Uppdaterat

Litteratursökningsdatum: 9/20/2019

Litteratursökningsdatum: 9/20/2019
Fasstexter

Visa fasstexter

Se även

Levetiracetam

Oxkarbazepin

C C
C C

Lamotrigin Testmiljö

Lamotrigin

Klass : C

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Crisomet, Labileno, Lamictal, Lamictal 25 mg disperguojamosios, Lamoca......

Crisomet, Labileno, Lamictal, Lamictal 25 mg disperguojamosios, Lamocare, Lamotrigin 1A Farma, Lamotrigin 2care4, Lamotrigin Abacus Medicine, Lamotrigin Actavis, Lamotrigin Aristo, Lamotrigin Arrow, Lamotrigin Aurobindo, Lamotrigin BMM Pharma, Lamotrigin Bluefish, Lamotrigin EQL, Lamotrigin Ebb, Lamotrigin Hexal, Lamotrigin Medochemie, Lamotrigin Mylan, Lamotrigin Orifarm, Lamotrigin Orion, Lamotrigin Teva, Lamotrigin ratiopharm
ATC-koder

N03AX09

N03AX09
Substanser

lamotrigin

lamotrigin
Sammanfattning

Det saknas studier som jämför den krampförebyggande effekten mellan män och kvinnor. En studie har visat att män svarar bättre än kvinnor på behandling med lamotrigin vid svårbehandlad bipolär affektiv sjukdom. Den övergripande biverkningsprofilen för lamotrigin är likartad för män och kvinnor. Yrsel har i en studie rapporterats vara vanligare hos kvinnor. Under graviditet sjunker vanligen koncentrationen av lamotrigin, tät monitorering av detta och korrigering av dos krävs för att upprätthålla krampförebyggande effekt. Post-partum måste dosen normaliseras för att undvika överdosering.

Det saknas studier som jämför den krampförebyggande effekten mellan män och kvinnor. En studie har visat att män svarar bättre än kvinnor på behandling med lamotrigin vid svårbehandlad bipolär affektiv sjukdom. Den övergripande biverkningsprofilen för lamotrigin är likartad för män och kvinnor. Yrsel har i en studie rapporterats vara vanligare hos kvinnor. Under graviditet sjunker vanligen koncentrationen av lamotrigin, tät monitorering av detta och korrigering av dos krävs för att upprätthålla krampförebyggande effekt. Post-partum måste dosen normaliseras för att undvika överdosering.
Background

Pharmacokinetics and dosing
Population analysis shows that pharmacokinetics of lamotrigine is similar in men and women [1-3]. However, a meta-analysis found that the volume of distribution was 27% lower in women than men. This difference persisted even when the effect of weight was taken into account. In all, 22/289 women were receiving concomitant therapy with various oral contraceptives. But in this study, oral contraceptives exhibited little effect on the pharmacokinetics of lamotrigine [3]. Dose adjustment based on patient’s sex appear to be unnecessary [2, 3]. During pregnancy, elimination of lamotrigine is increased necessitating therapeutic drug monitoring and dose adjustment, se below.

Effects
A small U.S. randomized clinical trial (18 men, 27 women, aged 20-67 years) has analysed possible clinical predictors of positive response to lamotrigine monotherapy in adults with refractory affective bipolar disorder. Male sex was associated with good response to lamotrigine [4].

Adverse effects
In a randomized parallel study conducted by the pharmaceutical company comparing pl......

Visa hela bakgrundstexten

# Pharmacokinetics and dosing Population analysis shows that pharmacokinetics of lamotrigine is similar in men and women [1-3]. However, a meta-analysis found that the volume of distribution was 27% lower in women than men. This difference persisted even when the effect of weight was taken into account. In all, 22/289 women were receiving concomitant therapy with various oral contraceptives. But in this study, oral contraceptives exhibited little effect on the pharmacokinetics of lamotrigine [3]. Dose adjustment based on patient’s sex appear to be unnecessary [2, 3]. During pregnancy, elimination of lamotrigine is increased necessitating therapeutic drug monitoring and dose adjustment, se below. # Effects A small U.S. randomized clinical trial (18 men, 27 women, aged 20-67 years) has analysed possible clinical predictors of positive response to lamotrigine monotherapy in adults with refractory affective bipolar disorder. Male sex was associated with good response to lamotrigine [4]. # Adverse effects In a randomized parallel study conducted by the pharmaceutical company comparing placebo and 300 and 500 mg/day of lamotrigine, the overall adverse reaction profile for lamotrigine was similar between women and men. The only adverse reaction for which the reports were greater than 10% more frequent in women than men was dizziness (difference = 16.5%) [1]. A retrospective analysis of patients on antiepileptic drug treatment showed fertile women to have a higher risk for skin reactions than men when treated with lamotrigine [5]. # Reproductive health issues Semen quality, sexual function and sex hormones in men with epilepsy are not affected by treatment with lamotrigine, levetiracetam, or oxcarbazepine, according to a randomized controlled trial including 38 adult men with newly diagnosed epilepsy [6]. Reports of sexual dysfunction caused by levetiracetam or oxcarbazepine are limited to case reports. Larger studies suggest that lamotrigine, levetiracetam and oxcarbazepine can improve sexual function [6, 7].  During pregnancy, clearance of lamotrigine increases progressively until the 32nd gestational week when it may be 2-3 times higher than pre-pregnancy levels. This is caused by induction of glucuronidation. After delivery the lamotrigine elimination rate drops rapidly and reach the pre-pregnant levels within the first 2-3 weeks postpartum [3, 8]. During mid and late pregnancy, serum concentrations of lamotrigine may decline to 30-50% of pre-pregnancy levels, with an increased frequency of seizures [8, 9]. Therefore, close monitoring of lamotrigine concentrations throughout the entire pregnancy and postpartum is recommended [10]. Lamotrigine has little effect on mixed-function oxygenase enzymes, it would not be expected that estrogen and progestin clearance would be altered. Previous investigation suggests that lamotrigine has no effect on the clearance of ethinyl estradiol and levonorgestrel (30/150 µg) and no alternations in menstrual pattern were noted [9].  Regarding drug-drug interactions aspects, please consult Janusmed Interactions (in Swedish, Janusmed interaktioner). Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler kvinnor än män hämtade ut tabletter innehållande lamotrigin (ATC-kod N03AX09) på recept i Sverige år 2019, totalt 37 215 kvinnor och 22 114 män. Det motsvarar 7,3 respektive 4,3 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 25-34 år hos båda könen. I genomsnitt var tabletter innehållande lamotrigin 1,7 gånger vanligare hos kvinnor [11].
Referenser

Visa referenser

  1. Lamictal (lamotrigine). DailyMed [www]. U.S. National Library of Medicine. [updated 2019-08-27, cited 2019-09-20].

  2. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol. 1997;43:457-65.

  3. Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol. 1999;39:373-84.

  4. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002;51:253-60.

  5. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007;48:1360-5.

  6. Wu D, Chen L, Ji F, Si Y, Sun H. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Epilepsia. 2018;59(7):1344-1350.

  7. Yogarajah M, Mula M. Sexual Dysfunction in Epilepsy and the Role of Anti-Epileptic Drugs. Curr Pharm Des. 2017;23(37):5649-5661.

  8. Sabers A, Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol. 2009;22:157-61.

  9. Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS, editor. Handbook of Clinical Gender Medicine. 1st ed. Karger; 2012.

  10. Pennell PB. 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia. 2006;47 Suppl 1:46-53.

  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Lamictal (lamotrigine). DailyMed [www]. U.S. National Library of Medicine. [updated 2019-08-27, cited 2019-09-20].
  2. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol. 1997;43:457-65.
  3. Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol. 1999;39:373-84.
  4. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002;51:253-60.
  5. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007;48:1360-5.
  6. Wu D, Chen L, Ji F, Si Y, Sun H. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Epilepsia. 2018;59(7):1344-1350.
  7. Yogarajah M, Mula M. Sexual Dysfunction in Epilepsy and the Role of Anti-Epileptic Drugs. Curr Pharm Des. 2017;23(37):5649-5661.
  8. Sabers A, Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol. 2009;22:157-61.
  9. Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS, editor. Handbook of Clinical Gender Medicine. 1st ed. Karger; 2012.
  10. Pennell PB. 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia. 2006;47 Suppl 1:46-53.
  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]
Uppdaterat

Litteratursökningsdatum: 9/20/2019

Litteratursökningsdatum: 9/20/2019
Fasstexter

Visa fasstexter

Se även

Levetiracetam

Oxkarbazepin